Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 9/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 9/20 | 0.41 |
| ▸ | POLA1 | P09884 | 6/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15980588 | 0.82 | POLA1 (0.41) | CYP3A4ALDH1A1NR1H2NR1H3POLA1 | |
| SCHEMBL806818 | 0.82 | POLA1 (0.41) | CYP3A4ALDH1A1NR1H2NR1H3POLA1 | |
| SCHEMBL15978294 | 0.82 | SRD5A1 (0.49) | NR1H2NR1H3 | |
| SCHEMBL806506 | 0.82 | SRD5A1 (0.49) | NR1H2NR1H3 | |
| SCHEMBL15978308 | 0.82 | POLA1 (0.63) | CYP3A4ALDH1A1NR1H2NR1H3POLA1 | |
| SCHEMBL15978289 | 0.73 | SRD5A1 (0.44) | NR1H2NR1H3 | |
| SCHEMBL24591878 | 0.73 | LMNA (0.65) | CYP3A4NR1H2NR1H3POLA1PDE4D | |
| SCHEMBL24591986 | 0.68 | NR1H2 (0.69) | NR1H2NR1H3POLA1 | |
| SCHEMBL15978303 | 0.67 | SRD5A1 (0.46) | NR1H2NR1H3 | |
| SCHEMBL806508 | 0.67 | SRD5A1 (0.46) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243404-A1 | UNIQUE HALOGEN-INDUCED CYCLIZATIONS, REAGENTS THEREFOR, AND COMPOUNDS PRODUCED THEREBY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243404-A1 | UNIQUE HALOGEN-INDUCED CYCLIZATIONS, REAGENTS THEREFOR, AND COMPOUNDS PRODUCED THEREBY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243404-A1 | UNIQUE HALOGEN-INDUCED CYCLIZATIONS, REAGENTS THEREFOR, AND COMPOUNDS PRODUCED THEREBY | WEE1, WEE2, NOTUM | CYP3A4 421/4885ALDH1A1 1556/4885NR1H2 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.